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Available online 14 April 2016Objective: The aim of this studywas to evaluate long-term safety, efﬁcacy, and quality of life (QOL) of ≤400-mg/day
USL255, Qudexy® XR (topiramate) extended-release capsules, as adjunctive therapy for partial-onset seizures
(POS) in adults.
Methods: Patients who completed the 11-week double-blind treatment phase of the phase 3 PREVAIL study were
eligible to enroll in this 1-year open-label extension (OLE) study (PREVAIL OLE). The primary objective was to eval-
uate the safety and tolerability of USL255 (including treatment-emergent adverse events [TEAEs]). The secondary
objective was to assess seizure frequency in patients (e.g., median percent reduction from baseline in weekly POS
frequency, responder rate [proportion of patients with ≥25%, ≥50%, ≥75%, or 100% reduction from baseline in POS
frequency], and seizure-free intervals [proportion of patients who were seizure-free for 4, 12, 24, 36, or
48 weeks]). Exploratory clinical-status endpoints included the Global Impression of Change (CGI-C) and Quality
of Life in Epilepsy—Problems (QOLIE-31-P) questionnaires. Post hoc analyses evaluated neurocognitive TEAE inci-
dences during the ﬁrst 11 and entire 55 weeks of treatment and efﬁcacy by patient age and drug-resistant status.
Results: Of the 217 patients who completed PREVAIL (USL255, n = 103; placebo, n = 114), 210 (97%) enrolled in
PREVAILOLEandwere included in the ITTpopulation. Across the entire 55-week treatment period, USL255wasgen-
erally safe andwell tolerated, with low individual neurocognitive TEAE incidences. Seizure reductionwas sustained
across the year-long study and observed in patient subgroups, including those with highly drug-resistant seizures
and those ≥50 years of age. Improvements in CGI-C and QOLIE-31-P were also observed.
Signiﬁcance: The results of PREVAIL OLE are consistent with those from PREVAIL and demonstrate that adjunctive
treatment with up to 400 mg/day of USL255 may be a safe and effective treatment option for a variety of adult pa-
tients with refractory POS.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Extended release1. Introduction
Up to 30% of patients with epilepsy still experience seizure activity
despite antiepileptic drug (AED) treatment [1], and seizures in others
remain completely resistant to currently available treatments [2]. Un-
controlled seizures occur at severe psychosocial cost to patients [3],ix, AZ 85006, USA. Tel.:+1 602
hung).
EVAIL OLE Study Group.
. This is an open access article underwho would beneﬁt from any reduction in seizure activity. Extended-
release formulations of AEDs are designed to reduce dosing frequency
and maintain relatively consistent drug plasma concentrations, which
may reduce breakthrough seizures, cognitive-related and other adverse
events (AEs), and improve overall quality of life (QOL). USL255,
Qudexy® XR (topiramate) extended-release capsules (Upsher-Smith,
Maple Grove, MN, U.S.A. [4]), is an extended-release, once-daily formu-
lation of the well-established AED topiramate. USL255 is a proprietary
multiparticulate (beads in a capsule) formulation,whichwas developed
to deliver consistent drug release over a 24-h dosing interval. USL255
provides an overall plasma topiramate exposure that is equivalentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mum concentration (Cmax) and higher minimum concentration (Cmin),
resulting in decreased ﬂuctuations in drug plasma concentrations [5,6].
The efﬁcacy and favorable tolerability of 200-mg/day USL255 as ad-
junctive therapy for partial-onset seizures (POS) were demonstrated in
a randomized, double-blind, placebo-controlled, multicenter, 11-week
phase 3 study (PREVAIL). A longer-term safety evaluation is important
because certain TEAEs can be delayed, particularly when topiramate is
used as add-on treatment [7]. Moreover, topiramate may be associated
with neurocognitive-related treatment-emergent AEs (TEAEs) [8] that
can continue over the long term [9,10]. Therefore, this year-long open-
label extension (OLE) study (PREVAIL OLE) was conducted to evaluate
the long-term safety and efﬁcacy of ≤400-mg/day USL255 as adjunctive
therapy for POS. In addition, post hoc analyses examining new onset
(incidence) of neurocognitive TEAEs and seizure reduction in various
patient subgroups were performed.
2. Methods
2.1. Trial conduct
The PREVAIL OLE study was conducted from October 2010 toMarch
2014 at 54 study centers in 15 countries (Argentina, Australia, Canada,
Chile, Germany, Greece, Hungary, India, Israel, New Zealand, Poland,
Russia, South Africa, Spain, and the United States). This study was con-
ducted in accordance with the International Conference on Harmoniza-
tion E6 Guideline for Good Clinical Practice and applicable regulatory
requirements. The institutional review boards and the European
Research Council supervised and safeguarded the rights, safety, and
well-being of all study subjects. Prior to any screening procedures, all
patients provided written informed consent. The PREVAIL OLE study is
registered with ClinicalTrials.gov (NCT01191086).
2.2. Patients
Eligible patients were those who completed the 11-week double-
blind treatment phase (three weeks titration + eight weeks
maintenance) of the PREVAIL study (ClinicalTrails.gov identiﬁer:
NCT01142193). Detailed methods of PREVAIL have been described
previously [11]. Brieﬂy, adults (18–75 years of age at time of entry
into PREVAIL) with a conﬁrmed diagnosis of refractory POS for at least
one year on a stable regimen of 1–3 concomitant AEDs were eligible
to enroll in PREVAIL and continue into the OLE. Eligible patients had a
minimum of eight POS and no more than 21 consecutive seizure-free
days during the 8-week baseline period of PREVAIL. Seizures classiﬁed
as simple partial with motor signs, complex partial, or partial with
secondary generalization qualiﬁed patients to meet inclusion criteria.
Patients could have had more than one seizure type.
2.3. Study design
Upon entry into PREVAIL OLE (following 11weeks of USL255 or pla-
cebo treatment in PREVAIL), patients underwent a 3-week blinded-
conversion phase followed by a 52-week open-label phase. During
blinded conversion, patients previously randomized to placebo in
PREVAIL were titrated in 50-mg/week increments to 200-mg/day
USL255, and patients previously randomized to 200-mg/day USL255
in PREVAIL continued treatment. Following blinded conversion, open-
label maintenance at 200-mg/day USL255 for eight weeks was required
for all patients. After 11 weeks of the OLE (3-week blinded conversion +
+8-week maintenance), USL255 dosages were allowed to be titrated up
or down by 50 mg/week, up to a maximum daily dosage of 400 mg/day.
Concomitant AEDs (except vigabatrin, felbamate, and topiramate) could
be added, removed, or dose-adjusted (but not within 3 days of a change
in USL255 dose) as long as patients remained on 1–3 concomitant AEDs.
At the end of the 55-week OLE, patients were tapered off USL255by 50mg/week over the course of at least three weeks or, with physician
approval, were converted directly to the equivalent daily dose of
immediate-release topiramate without taper.
2.4. Assessments
The primary objective of the study was to evaluate the safety and
tolerability of USL255 as adjunctive treatment in patients with POS.
Primary endpoints examined included spontaneously reported TEAEs,
clinical laboratory values, vital signs, physical/neurological examina-
tions, and suicidality assessments via the Columbia Suicide Severity
Rating Scale (C-SSRS). Treatment-emergent adverse events were
summarized by frequency, treatment relatedness, and maximum
severity. Post hoc safety analyses included incidence (new onset) of
neurocognitive TEAEs for the ﬁrst 11 weeks of USL255 treatment (for
newly exposed patients [PBO-USL]) and for the duration of PREVAIL OLE.
The secondary objective of the studywas to assess seizure frequency
in patients with POS receiving open-label USL255. Secondary endpoints
included various seizure frequency outcomes (documented through pa-
tient diaries), the median percent reduction from baseline in weekly
POS frequency, and responder rate (proportion of patients with ≥25%,
≥50%, ≥75%, or 100% reduction from baseline inweekly POS frequency);
analyses included all patient data regardless of trial completion. Base-
line was deﬁned as the 8-week baseline period prior to the start of PRE-
VAIL. Patients were also evaluated for seizure-free intervals (deﬁned as
the percentage of patients who were seizure-free for an interval of 4,
12, 24, 36, or 48 weeks at any time during the study). For the efﬁcacy
analyses, treatment periods evaluated included the 3-week blinded con-
version phase, the 52-week open-label phase, and the overall 55weeks of
PREVAIL OLE (blinded conversion+ open-label). For the 52-week open-
label phase, seizure rates also were calculated during each consecutive
12-week interval. Post hoc efﬁcacy analyses includedmedian percent re-
duction frombaseline inweekly POS frequency and responder rate by pa-
tient age (18 to b35, 35 to b50, and ≥50 years of age) and by drug
refractoriness. Based on a surrogate measure of drug refractoriness (the
number of current and lifetime AEDs), patients were divided into two
groups: patients with ≥2 concurrent AEDs and ≥4 lifetime AEDswere de-
ﬁned as having “highly” drug-resistant seizures, while the rest of the
study population comprised the group of patients with “less” drug-
resistant seizures (one concurrent AED and/or b4 lifetime AEDs) [12].
Exploratory clinical-status endpoints included the clinician-reported
Global Impression of Change (CGI-C) and the patient-reported Quality
of Life in Epilepsy—Problems (QOLIE-31-P) questionnaires, both per-
formed at baseline and week 55 or early termination (ET, if applicable).
The CGI-C was used to evaluate patient clinical status by assessing
seizure frequency and severity, occurrence of adverse events, and over-
all functional status. The CGI-C is a 7-point scale with lower scores
indicating greater improvement; scores range from 1= very much im-
proved to 7 = very much worse. The QOLIE-31-P was used to evaluate
change from baseline in QOL and was completed by patients in coun-
tries where it was available and validated for the spoken language(s).
The QOLIE-31-P is composed of seven subscales (seizure worry, overall
quality of life, emotions, energy, mental activity, medication effects, and
daily activities), and higher scores indicate greater well-being.
2.5. Data analyses
Safety and tolerability, efﬁcacy, and QOL analyses were performed
using the intent-to-treat (ITT) population, deﬁned as all patients who
received at least one dose of USL255 in PREVAIL OLE. Subgroup analyses
included patients who were randomized to USL255 in PREVAIL
(USL-USL) and patients who were randomized to placebo in PREVAIL
(PBO-USL). The 8-week baseline period prior to the start of treatment
in PREVAIL was used as baseline for all PREVAIL OLE endpoints. Descrip-
tive statistics were calculated for all assessments, and endpoints were
summarized using an observed cases analysis.
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3.1. Demographics, patient disposition, and exposure
Of the 217 patients who completed PREVAIL (USL255, n= 103; pla-
cebo, n= 114), 210 (97%) chose to enroll in the OLE and were included
in the ITT population. Patient demographics and baseline characteristics
are shown in Table 1. Overall, patients had difﬁcult-to-treat seizures, as
the mean duration of epilepsy was 21 years; 20% of the overall popula-
tion had taken at least seven lifetime AEDs; and 74% were on an AED
regimen with at least two concomitant AEDs. Carbamazepine was the
most commonly used AED in this population (45.2%). This was followed
by valproic acid and its derivatives (33.3%), lamotrigine (27.1%), leveti-
racetam (21.9%), phenobarbital (16.2%), oxcarbazepine (12.4%),
lacosamide (10.5%), and others used by b10%. Only modest differences
were observed between the USL-USL and PBO-USL subgroups. A total
of 150 patients (71%) completed PREVAIL OLE (76% USL-USL and 68%
PBO-USL; Table 1). The most common reasons for discontinuation
were voluntary withdrawal by the patient (11%) and AEs (9.5%), with
more patients in the PBO-USL subgroup discontinuing because of AEs
than those in the USL-USL subgroup (Table 1). The mean duration of
patient exposure to USL255 during PREVAIL OLE was 336 days for
those given active treatment during PREVAIL (USL-USL) and 320 days
for those who had been given placebo (PBO-USL). At the end of
PREVAIL OLE, 84% of patients had been exposed to USL255 for more
than 180 days. Similar percentages of patients assigned to receive
USL255 or placebo in the PREVAIL study experienced a change inTable 1
Patient demographics, baseline characteristics, and disposition.
USL-USL
subgroup
n = 99
PBO-USL
subgroup
n = 111
Total
N = 210
Demographics and characteristics
Age, yeara, mean (SD) 38 (12) 37 (11) 38 (11)
Male, n (%) 57 (58) 57 (51) 114 (54)
White, n (%) 83 (84) 97 (87) 180 (86)
Duration of epilepsy, yearb, mean (SD) 22 (14) 20 (13) 21 (13)
Weekly POS frequency at baselinea,
median (range)
2.3 (1.0–23) 2.8 (0.9–37) 2.5 (0.9–37)
Concomitant AEDs at start of PREVAIL
OLE, n (%)
1 20 (20) 34 (31) 54 (26)
2 54 (55) 46 (41) 100 (48)
≥3c 25 (25) 31 (28)c 56 (27)c
AEDs tried during lifetimea, n (%)
≤3 54 (55) 42 (38) 96 (46)
4–6 30 (30) 43 (39) 73 (35)
≥7 15 (15) 26 (23) 41 (20)
Disposition
Received study drug, n 99 111 210
Completed studyd, n (%) 75 (76) 75 (68) 150 (71)
Discontinued from study, n (%) 24 (24) 36 (32) 60 (29)
Reasons for discontinuation, n (%)
Withdrawal by patient 10 (10) 14 (13) 24 (11)
Adverse event 4 (4.0) 16 (14) 20 (9.5)
Lack of efﬁcacy 6 (6.1) 4 (3.6) 10 (4.8)
Lost to follow-up 2 (2.0) 2 (1.8) 4 (1.9)
Physician decision 1 (1.0) 1 (0.9) 2 (1.0)
Protocol discontinuation criterion/criteria
met
1 (1.0) 0 1 (0.5)
Other 1 (1.0) 0 1 (0.5)
All patients received USL255 during the OLE. USL-USL subgroup deﬁned as patients who
were previously randomized to USL255 in PREVAIL. PBO-USL subgroupdeﬁned as patients
whowere previously randomized to placebo in PREVAIL. Abbreviations: AED, antiepileptic
drug; POS, partial-onset seizure; SD, standard deviation.
a Values from baseline of PREVAIL.
b Duration of epilepsy is computed as year of diagnosis to year of screening in PREVAIL.
c One participant in the PBO-USL Subgroup reported taking 4 concomitant AEDs at
study start (protocol deviation).
d Completing the study was deﬁned as completing the open-label treatment phase.USL255 dose during the OLE (USL-USL subgroup, 72%; PBO-USL sub-
group, 69%). The percentage of total patients having a dose increase
(70%) was nearly double the number of patients having a dose decrease
(33.3%). A total of 63 patients (30%) increased their dose to the 300- to
350-mg dose range, and 15 patients (7.1%) increased to the ≥400-mg
USL255 dose at some point during PREVAIL OLE (two subjects violated
protocol with a N400-mg dose).
3.2. Safety and tolerability assessments
3.2.1. Adverse events
Over the course of the study, 146 patients (69.5%) reported at least
one TEAE (Table 2), 90% of which were described as mild or moderate
in intensity. At least one treatment-related TEAE was experienced by
102 patients (48.6%). A total of 16 serious adverse events (SAEs) were
reported by 14 patients (Table 2), of which only two events were
deemed related to USL255 treatment (cholelithiasis and volvulus,
n = 1 [0.5% of all patients] each). Of the 9.5% of all patients who
discontinued the PREVAIL OLE study because of adverse events, aphasia,
asthenia, convulsion, and diarrhea were the only TEAEs leading to dis-
continuation in more than one patient (n = 2 [1%] each). For the most
commonTEAEs, aphasia, fatigue, and somnolence had higher incidences
in patients newly exposed to USL255 in PREVAIL OLE (PBO-USL) versus
those continuing treatment from PREVAIL (USL-USL) (Table 2).
3.2.2. Neurocognitive adverse events
Over the 55-week treatment period, the incidence of any individual
with at least one neurocognitive-related TEAE was 12.9% of the total
population (Table 3). The only neurocognitive-related TEAE that was
deemed “severe” by maximum intensity was aphasia, which was expe-
rienced in 2 individuals newly exposed to USL255 in the PREVAIL OLE
(PBO-USL subgroup, 1% of the total population). The incidence of
neurocognitive TEAEs leading to study discontinuation was 2% of the
total population, all of which occurred in four patients that received pla-
cebo during PREVAIL (PBO-USL: aphasia, n = 2; bradyphrenia, n = 1;
cognitive disorder, n = 1). Incidences for individual neurocognitive
TEAEs were all b3%, with the exception of aphasia (5.2%). Post hoc
analyses compared the incidence of new onset neurocognitive TEAEs
following early USL255 exposure vs. extended periods of exposure
(Table 3). In patients newly exposed to USL255 (PBO-USL), the overall
neurocognitive TEAE incidence was 9.9% during the ﬁrst 11 weeks of
PREVAIL OLE and 10.1% during the remainder of the study (lastTable 2
Summary of TEAEs reported during PREVAIL OLEa.
USL-USL
subgroup
n = 99
PBO-USL
subgroup
n = 111
Total
N = 210
Patients with ≥1 TEAE, n (%) 61 (61.6) 85 (76.6) 146 (69.5)
Patients with ≥1 treatment-related
TEAEb, n (%)
42 (42.4) 60 (54.1) 102 (48.6)
Patients reporting any SAE, n (%) 6 (6.1) 8 (7.2) 14 (6.7)
TEAEs reported in ≥5% of total
patients, n (%)
Headache 8 (8.1) 8 (7.2) 16 (7.6)
Weight decreased 8 (8.1) 8 (7.2) 16 (7.6)
Somnolence 5 (5.1) 10 (9.0) 15 (7.1)
Dizziness 6 (6.1) 7 (6.3) 13 (6.2)
Aphasia 0 11 (9.9) 11 (5.2)
Fatigue 2 (2.0) 9 (8.1) 11 (5.2)
All patients received USL255 during PREVAIL OLE. USL-USL subgroup deﬁned as patients
who were previously randomized to USL255 in PREVAIL. PBO-USL subgroup deﬁned as
patients who were previously randomized to placebo in PREVAIL. Abbreviations: SAE,
serious adverse event; TEAE, treatment-emergent adverse event.
a TEAEs deﬁned as AEs with onset after the start of treatment in PREVAIL OLE and up to
30 days after the last dose.
b Adverse events with causality assessments of possibly, probably, deﬁnitely, or unknown
were considered treatment-related.
Table 3
Onset of neurocognitive-related TEAEs.
n (%) USL-USL subgroup PBO-USL subgroup Total
N = 210
Entire 55 weeks
n = 99
First 11 weeks
n = 111
Last 44 weeks
n = 99
Total in PBO-USL
n = 111
Patients with ≥1 neurocognitive-related TEAE 6 (6.1) 11 (9.9) 10 (10.1) 21 (18.9) 27 (12.9)
Aphasia 0 7 (6.3) 4 (4) 11 (9.9) 11 (5.2)
Memory impairment 2 (2) 1 (0.9) 2 (2) 3 (2.7) 5 (2.4)
Cognitive disorder 1 (1) 1 (0.9) 2 (2) 3 (2.7) 4 (1.9)
Disturbance in attention 1 (1) 1 (0.9) 2 (2) 3 (2.7) 4 (1.9)
Speech disorder 2 (2) 0 0 0 2 (1.0)
Amnesia 1 (1) 0 1 (1) 1 (0.9) 2 (1.0)
Bradyphrenia 0 1 (0.9) 0 1 (0.9) 1 (0.5)
Dysarthria 0 0 1 (1) 1 (0.9) 1 (0.5)
Psychomotor slowing 0 1 (0.9) 0 1 (0.9) 1 (0.5)
All patients received USL255 during PREVAIL OLE. USL-USL subgroup deﬁned as patients who were previously randomized to USL255 in PREVAIL. PBO-USL subgroup deﬁned as patients
who were previously randomized to placebo in PREVAIL. Abbreviation: TEAE, treatment-emergent adverse event.
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ﬁrst 11 weeks of exposure (during the PREVAIL study [11]) and 6.1%
during the remainder of treatment exposure (ie the 55 weeks of PRE-
VAIL OLE, Table 3). Overall, the incidence of neurocognitive TEAEs
remained relatively consistent over time as patients continued treat-
ment, although rates were slightly higher for patients newly exposed
to the study drug in PREVAIL OLE (10.1% for PBO-USL [last 44 weeks]
vs. 6.1% for USL-USL [entire 55 weeks], Table 3). The incidence of any
speech disturbance (aphasia, dysarthria, and/or speech disorder: PBO-
USL: 6.3% for the ﬁrst 11 weeks and 5.1% for the last 44 weeks; USL-
USL: 2% [55 weeks]) was similar to the results for aphasia alone.
3.2.3. Additional safety and tolerability assessments
Safety concerns associated with long-term topiramate use include
metabolic acidosis, kidney stones, decreased sweating, and increased
body temperature [13], and none were reported during the 55-week
OLE. Although mean alkaline phosphatase, blood urea nitrogen, chlo-
ride, and creatinine levelswere increased frombaseline and bicarbonate
levels were decreased from baseline, the changes were not signiﬁcant
or unexpected, as serum chemistry parameters can be affected by
topiramate. Overall, urinalysis andmean hematology valueswerewith-
in reference ranges, with the exception of red blood cell distribution
width (high at baseline [15%] and increased slightly from baseline
[0.14%]). For vital sign assessments, 8 patients had a ≥20% clinically sig-
niﬁcant increase or decrease from baseline in systolic blood pressure
(n= 2, either ≥150 or ≤90mmHg), diastolic blood pressure (n= 5, ei-
ther ≥100 or ≤60mmHg), or heart rate (n=1, either ≥120 or ≤50 beats
per minute). Decreases in body weight have been reported with
topiramate use [13] and were observed regardless of prior PREVAIL
treatment (change from PREVAIL baseline in USL-USL subgroup:
−5.4%, PBO-USL subgroup:−4.0%). For both the physical and neuro-
logical examinations, ﬁve patients (2.4% each) experienced clinically
signiﬁcant changes from baseline. Although no patients experienced
suicidal behavior during PREVAIL OLE, one patient reported suicidal
ideation. One death occurred during the OLE (ischemic stroke) and
was deemed unrelated to USL255.
3.3. Efﬁcacy assessments
Across the 55-week OLE study, the median percent reduction in
weekly POS frequency was 56% for the total population. The median
percent reduction from the PREVAIL baseline was 51% during the
3-week blinded-conversion phase and 59% across the 52-week open-
label phase of the OLE. During the 52-week open-label phase, seizureFig. 1. Seizure reduction during the 52-week open-label phase. Rate of seizure frequency durin
responder rate (B) by 12-week intervals and the proportion of patientswith ≥25%, ≥50%, ≥75%, o
USL-USL (red) and PBO-USL (blue) subgroups are deﬁned as patients who were previously ranreduction was relatively consistent across all weeks, regardless of
prior double-blind treatment (Fig. 1A). Similar trends were observed
for 50% responder rate (Fig. 1B), which was relatively consistent for all
patients across the ﬁrst three weeks (52%), the 52-week open-label
phase (62%), and the entire 55-week study (58%), regardless of prior
treatment. The 25%, 50%, 75%, and 100% responder rates for all patients
during the open-label treatment phase are presented in Fig. 1C. The pro-
portion of patients with a 100% reduction in seizure frequency from
baseline to completion or early withdrawal during the open-label
phase was 5% (Fig. 1C). However, patients did experience seizure-free
intervals of varying durations during the 55-week OLE. The percentage
of all patients who experienced seizure-free intervals of 4, 12, 24, 36,
and 48 weeks was 51%, 19%, 11%, 7.2%, and 2.4%, respectively.
3.3.1. Efﬁcacy by drug resistance and patient age
In post hoc analyses of efﬁcacy by drug-resistant status compared to
PREVAIL baseline, seizure reductionwas observed early (during 3-week
blinded-conversion phase) and remained relatively consistent across
the study, regardless of whether patients were deemed to have highly
drug-resistant seizures or less drug-resistant seizures (Fig. 2A). Seizure
reduction during the entire OLE also was not greatly impacted by
patient age; during the 52-week open-label phase, the rate of seizure re-
duction was similar among all age groups evaluated, although during
theﬁrst threeweeks of treatment, the ratewas slightly lower in patients
at least 50 years of age (Fig. 2B). However, the number of patients in this
age group (n = 31) was approximately one-third of that in the 18- to
b35-year age group (n = 94) and 35- to b50-year age group (n =
84). Nearly identical trends were observed for 50% responder rate
when evaluated by drug refractoriness (during 55-week OLE: highly
drug-resistant seizures, 66.1%; less drug-resistant seizures, 47.9%) and
patient age (during 55-week OLE: 18 to b35 years, 61.7%; 35 to
b50 years, 56%; ≥50 years, 51.6%).
3.3.2. Clinical and quality-of-life assessments
For the subset of patients (n= 92) who had evaluable investigator-
based CGI-C ratings atweek 55, 45 (49%)were rated as ‘much improved’
or ‘very much improved’ from baseline. In addition, these ratings were
similar for all patients during PREVAIL OLE, regardless of prior double-
blind treatment during PREVAIL (45% USL-USL [n = 21] vs. 53.3%
PBO-USL [n = 24]). A total of 88 patients completed the patient-rated
QOLIE-31-P survey at week 55, with improvements from baseline in
the mean overall score (5.0) and distress score (6.5, Fig. 3). The largest
subscale change from baseline in all patients was observed for the
seizure worry subscale (10.8, Fig. 3). Treatment with USL255 resultedg the 52-week open-label phase. Depicted are the median percent reduction (A) and 50%
r 100% reduction frombaseline in POS frequency (C) across the 52-week open-label phase.
domized to USL255 or placebo, respectively, in PREVAIL.
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Fig. 2. Seizure reduction by highly and less drug-resistant seizures and patient age. Depicted are the median percent reductions in weekly POS frequency during the 3-week blinded
conversion phase, the 52-week open-label phase, and the entire 55-week OLE (conversion + open-label phases). Post hoc analyses include median percent reduction in baseline
weekly POS frequency in (A) patients with highly and less drug-resistant seizures and (B) patients by age group.
18 S.S. Chung et al. / Epilepsy & Behavior 59 (2016) 13–20in a positive change from baseline for all subscales, except for the med-
ication effects subscale where there was a slight worsening in patients
newly exposed to USL255 in PREVAIL OLE (PBO-USL, Fig. 3).
4. Discussion
The results presented here are from theOLE study of PREVAIL, which
was a phase 3, randomized, placebo-controlled, double-blind, multina-
tional study evaluating the adjunctive treatment of 200-mg USL255 in
adults with refractory POS. Of the 217 patients who completed
PREVAIL, 210 (97%) enrolled in the OLE study — a strong indicator of
favorable outcomes. A total of 150 patients (71%) completed PREVAIL
OLE, which is in the range of retention rates (40–87%) reported follow-
ing one year of treatment in other open-label AED studies [14–20].
During PREVAILOLE, patients could increase or decrease USL255 dosage
to a maximum of 400 mg/day, though most patients remained below
300 mg/day. This suggests that 200–275 mg/day of USL255 may offer
an optimal maintenance add-on dosage for most patients.
USL255 was generally safe and well tolerated during the year-long
PREVAIL OLE. Approximately 70% of patients reported a TEAE, most of
which were mild or moderate in intensity. The most common TEAEs
during the PREVAIL OLE studywere headache, weight decrease, somno-
lence, dizziness, aphasia, and fatigue, though no single AE was reported
in more than 7.6% of all patients. These TEAEs are not unexpected, as
most are known to be associated with topiramate use (headache,
weight decrease, somnolence, dizziness, and fatigue) [13] and are simi-
lar to those reported in the 11-week PREVAIL study. The incidence of in-
dividual neurocognitive TEAEs was less than 3% of the total population,
with the exception of aphasia (5.2%). Further, the low incidence of
neurocognitive TEAEs in PREVAIL OLE was evident for the year-longstudy duration; the incidence was similar between the ﬁrst 11 weeks
and last 44 weeks in patients newly exposed to USL255 in PREVAIL
OLE (PBO-USL) and in patients newly exposed vs. those exposed during
PREVAIL (USL-USL). This low incidence is of particular interest, as
neurocognitive TEAEs including speech disorders, psychomotor
slowing, and disturbance in attention are associated with topiramate
[13]. In addition,metabolic acidosis and kidney stones – both associated
with long-term topiramate use [13] – were not observed in the year-
long PREVAIL OLE study. The low incidence of these TEAEs may owe
to selection bias, as patients at higher risk for these types of AEs (e.g.,
elderly, mentally handicapped individuals) may have been less likely
to participate in this long-term study; however, individualswere not in-
tentionally excluded because of age or cognitive abilities. It is possible
that AEs experienced during the study could have been due to concom-
itant medications, as AEs can often be additive or synergistic with
polytherapy [21]; the ability of patients to modify both the number
and dosage of AEDs following 11 weeks in PREVAIL OLE may be
reﬂected in the reduced percentage of patients whose TEAEs were
deemed treatment-related (49%). The total of 9.5% of patients who
discontinued because of an AE in this year-long study is in line with
data in the literature from open-label studies evaluating AEDs in pa-
tients with POS. which range from 3.5–32% [14–16,18–20,22–25]. How-
ever, it is important to note that direct comparisons across clinical trials
are difﬁcult because of differences in patient populations, trial design,
and duration of treatment.
The secondary objective of the studywas to assess seizure reduction.
Adjunctive treatmentwith up to 400mg of USL255 reducedweeklyme-
dian POS frequency by 56% across the 55-week OLE study, and 58% of
patients had at least a 50% reduction in seizure frequency (50% respond-
er rate). These results resemble those observed in patients randomized
Fig. 3. Change from baseline inQOLIE-31-P atweek 55.Mean changes from baseline inQOLIE-31-P for USL-USL and PBO-USL subgroups, as well as the two groups combined (“Total”). The
X- and Y-axes depict individual subscales andmean changes from baseline, respectively, in the QOLIE-31-P. USL-USL and PBO-USL subgroups are deﬁned as patients whowere previously
randomized to USL255 or placebo, respectively, in PREVAIL. Higher scores indicate greater well-being.
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tion: 39.5%, 50% responder rate: 37.9%) [11] and in other 1-year OLE
studies of AEDs (median % reduction: ~38–67%, 50% responder rate:
~38–53% [14,15,19,20]). Efﬁcacy also remained consistent throughout
the duration of PREVAIL OLE, as newly exposed patients (PBO-USL)
had seizure reduction rates that, when compared with the PREVAIL
baseline, were similar at each phase of PREVAIL OLE and also similar
to rates observed for patients previously exposed in PREVAIL (USL-USL)
[11]; it is possible, however, that concomitant AEDs may have contrib-
uted. Post hoc efﬁcacy analyses revealed that this long-term seizure
reduction was observed between adults of various age groups, as well
as between patients with less or highly drug-resistant seizures. Positive
seizure reduction seen in a subgroupwith highly drug-resistant seizures
suggests that difﬁcult-to-treat seizures may respond to treatment with
USL255.
Quality of life in patients with epilepsy is widely recognized as a
signiﬁcant component of disease management [26]. Improvements in
CGI-C and QOLIE-31-P also were reported for USL255 during PREVAIL
OLE, and mean changes in quality of life were generally in range with
QOLIE-31 results reported for other AEDs [15,20]. For patients with
evaluable CGI-C data at study completion, 49% were rated as ‘much
improved’ or ‘very much improved’ by investigators. The ‘seizure
worry’ QOLIE-31-P subscale, which assesses the impact of seizures on
QOL, had the largest positive change from baseline in the total patient
population during PREVAIL OLE. Moreover, USL255 did not negatively
impact the daily activities,mental activities, energy, emotions, or overall
quality-of-life subscales. Such enhancements in QOLmay help to reduce
the burden associated with inadequate seizure control.
Limitations of open-label studies include the lack of a placebo arm
for statistical comparisons, which may impact interpretation of long-
term efﬁcacy and patient awareness of receiving an active drug, which
may increase effects compared with randomized, double-blind studies.
Moreover, OLE studies can introduce a potential risk of bias that favors
the study drug when patients in the randomized patient sample from
the initial double-blind study are not all included in OLE analyses. For
example, while 97% of participants who completed PREVAIL entered
PREVAIL OLE, the 12.9% who discontinued PREVAIL (16.9% receiving
USL255, 8.8% receiving placebo) [11] may have done so because of AEs
or a lack of efﬁcacy. In addition, the potential effects of adjustments in
concomitant medications on long-term efﬁcacy cannot be controlledfor in an open-label study design. Despite these limitations, the long-
term evaluation of USL255 in an open-label setting, which allows for
dosage adjustments to both USL255 and concomitant AEDs, provides
safety and efﬁcacy data that better reﬂect clinical practice.
In regard to the post hoc analysis of efﬁcacy by drug refractoriness,
the authors acknowledge that the International League Against Epilepsy
(ILAE) deﬁnition of drug-resistant epilepsy (“failure of adequate trials of
two tolerated and appropriately chosen and used AED schedules”) [27]
was not used, as the PREVAIL OLE study design prevents veriﬁcation of
patient participation in two “adequate trials”. Therefore, the deﬁnition
for drug resistance in the post hoc analyses was based on clinical expe-
rience and a pharmacoeconomic study that classiﬁed ‘patients with
refractory seizures’ as those on three or more AEDs [12,28]. Despite
the limitations of deﬁning drug resistance, many patients responded
favorably to addition of USL255. Overall, the proportion of patients
with long-term seizure-free intervals of 4, 12, 24, 36, and 48 weeks
were 51%, 19%, 10%, 7.2%, and 2.4%, indicating that a number of subjects
demonstrated seizure freedom, especially in the earlier stages of the
study. This emphasizes the importance of continuing to administer
new AED combinations to subjects whose seizures have failed to
improve with multiple AEDs in the past.
The PREVAIL OLE results are consistent with the positive results of
the PREVAIL double-blind study results. Overall, the results of this
1-year PREVAIL OLE demonstrate that adjunctive treatment with up to
400 mg/day of USL255 has a favorable safety and tolerability proﬁle in
adultswith refractory POS. USL255 led to reductions in seizure frequency
thatwere similar at each phase of the year-long study— suggestive of ef-
ﬁcacy that is consistent and long-lasting. Further, USL255was efﬁcacious
in many patient subgroups, including those with the most difﬁcult-to-
treat seizures. These data suggest that once-daily USL255, Qudexy® XR
(topiramate) extended-release capsules, may be a safe and beneﬁcial
treatment option for the long-termmanagement of epilepsy in a variety
of adult patients with POS.
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